Cure­Vac spins a ma­jor set­back on their mR­NA Covid vac­cine in­to an ad­van­tage in the mar­ket wars to come

Af­ter strug­gling — and large­ly fail­ing — to make a case for their dis­ap­point­ing Covid-19 vac­cine, Cure­Vac is throw­ing in the tow­el and tak­ing a shot at com­ing up with some­thing vi­able for the glob­al mar­ket when coun­tries shift from pan­dem­ic to en­dem­ic vac­ci­na­tion cam­paigns.

Tues­day morn­ing the Ger­man mR­NA play­er — ac­com­pa­nied by a rep­re­sen­ta­tive of Glax­o­SmithK­line, which is al­lied on the work — ripped the ban­dage off a fes­ter­ing wound and re­treat­ed from an mR­NA vac­cine that fell short of the 50% pro­tec­tion mark, drop­ping their ap­pli­ca­tion for au­tho­riza­tion in Eu­rope and ax­ing a con­tract to de­liv­er more than 400 mil­lion dos­es of the jab.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER